# Nuclide record rituximab-then-ibritumomab-tiuxetan (pairing). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/pairings/rituximab-then-ibritumomab-tiuxetan/>
  a schema:MedicalTherapy ;
  nuclide:kind "pairing" ;
  schema:identifier "rituximab-then-ibritumomab-tiuxetan" ;
  schema:name "Rituximab pretreatment before ibritumomab tiuxetan (Zevalin)"@en ;
  schema:description "Before giving the radioactive lymphoma treatment Zevalin, doctors first give a dose of the antibody drug rituximab. This clears out normal B-cells in the blood so the radioactivity goes to the lymphoma more precisely, and it is a mandatory step on the drug's official label, not an optional extra."@en ;
  schema:url <https://nuclide.cc/pairings/rituximab-then-ibritumomab-tiuxetan/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125019s227lbl.pdf>, <https://ec.europa.eu/health/documents/community-register/2020/20200211147169/anx_147169_en.pdf> ;
  nuclide:tag "lymphoma", "radioimmunotherapy", "mandatory sequence" ;
  nuclide:related <https://nuclide.cc/targets/cd20/>, <https://nuclide.cc/indications/dlbcl/>, <https://nuclide.cc/indications/follicular-lymphoma/>, <https://nuclide.cc/technologies/radioimmunotherapy/>, <https://nuclide.cc/isotopes/y-90/> ;
  nuclide:pairs <https://nuclide.cc/drugs/rituximab/>, <https://nuclide.cc/drugs/ibritumomab-tiuxetan/> .